GeneTether Therapeutics Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 1.72 million compared to USD 1.64 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.05 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CAD | 0.00% | +22.22% | +37.50% |
1st Jan change | Capi. | |
---|---|---|
+37.50% | 1.57M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- GTTX Stock
- News GeneTether Therapeutics Inc.
- GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022